TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
MLYS

Mineralys Therapeutics, Inc.

Healthcare · Biotechnology

28.00$ +1.6% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Mineralys Therapeutics, Inc. (MLYS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.1% of the shares are freely tradable; institutional investors hold 110.0%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 110.0%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 75.1%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 12.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 88Mio.

Largest Shareholders

Institutions

Institutions MLYS
Name Stake (%) Shares Change (%) Date
Catalys Pacific LLC 8.94 7,903,838 +0.0 06/30/2026
RA Capital Management, LLC 8.70 7,692,750 +5.0 03/31/2026
Samsara BioCapital, LLC 6.64 5,871,018 +0.0 06/30/2026
FMR Inc 5.50 4,861,104 -3.9 03/31/2026
BlackRock Inc 5.07 4,481,582 +3.6 03/31/2026
State Street Corp 3.32 2,935,940 -7.8 03/31/2026
Vanguard Capital Management, LLC 2.78 2,454,363 +0.0 03/31/2026
LAURION CAPITAL MANAGEMENT LP 2.52 2,232,040 +30.3 03/31/2026
Orbimed Advisors LLC 2.32 2,052,900 +109.4 03/31/2026

Funds

Funds MLYS
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 3.36 2,968,478 -1.1 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings MLYS
Person Role Shares Value As of Type
Congleton Jon Chief Executive Officer 603,621 16,901,388 $ Jul 13, 2026 direct
Ferguson James J. III Chief Medical Officer 102,400 2,867,200 $ Aug 10, 2026 direct
Rodman David Malcom Chief Medical Officer 51,384 1,438,752 $ Aug 10, 2026 direct
Warren Eric Chief Commercial Officer 38,400 1,075,200 $ Aug 21, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Aug 21, 2026 Warren Eric Chief Commercial Officer Sell 7,437 25.98 193,189
Aug 21, 2026 Warren Eric Chief Commercial Officer Other 7,437 13.24 98,466
Aug 10, 2026 Ferguson James J. III Chief Medical Officer Other 102,400 0.00
Aug 10, 2026 Rodman David Malcom Chief Medical Officer Sell 2,170 27.09 58,785
Aug 10, 2026 Rodman David Malcom Chief Medical Officer Other 2,170 16.00 34,720
Jul 21, 2026 Warren Eric Chief Commercial Officer Sell 7,438 26.87 199,885
Jul 21, 2026 Warren Eric Chief Commercial Officer Other 7,438 13.24 98,479
Jul 17, 2026 Rodman David Malcom Chief Medical Officer Sell 416 26.53 11,036
Jul 17, 2026 Rodman David Malcom Chief Medical Officer Other 416 15.44 6,423
Jul 15, 2026 Rodman David Malcom Chief Medical Officer Sell 6,349 26.61 168,955
Jul 13, 2026 Congleton Jon Chief Executive Officer Sell 10,700 27.24 291,441
Jul 13, 2026 Rodman David Malcom Chief Medical Officer Sell 14,058 27.58 387,717
Jul 13, 2026 Rodman David Malcom Chief Medical Officer Other 6,349 1.08 6,857
Jul 13, 2026 Rodman David Malcom Chief Medical Officer Other 4,167 14.25 59,380
Jul 13, 2026 Rodman David Malcom Chief Medical Officer Other 3,542 10.20 36,128
Apr 17, 2026 David Malcom Rodman Insider Sell 416 31.33 13,033

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?